| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Avalo Therapeutics, Inc. (AVTX) has 9 insiders with recent SEC Form 4 filings, including 60 buys and 0 sells. AVTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 275.0K | $4.04M | - | |
| Other | 47.8K | $702.7K | -679 | |
| CFO | 19.1K | $281.0K | - | |
| Other | 3.6K | $53.4K | - | |
| Dir | 3.2K | $46.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 14, 2019 | Pedder Simon | Executive Chairman Of The Bd | Buy | 6,000 | $5.06 | $30,336.00 | New | |
| May 14, 2019 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 20,000 | $4.97 | $99,312.18 | - | |
| Mar 27, 2019 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 50,000 | $5.47 | $273,299.04 | - | |
| Mar 8, 2019 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 374,486 | $5.50 | $2,059,313.95 | +0.1% | |
| Jan 11, 2019 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 13,996 | $3.88 | $54,335.40 | - | |
| Jan 8, 2019 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 27,004 | $3.48 | $93,913.80 | - | |
| Dec 31, 2018 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 38,799 | $3.14 | $121,757.67 | - | |
| Dec 18, 2018 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 50,000 | $3.31 | $165,407.81 | - | |
| Dec 10, 2018 | Phillips Matthew V | Chief Commercial Officer | Buy | 497 | $2.85 | $1,415.21 | New | |
| Dec 10, 2018 | Harrell James Archie Jr | Exec. VP, Mktg &External Comm | Buy | 4,156 | $2.85 | $11,834.21 | New |